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Abstract 
 
Chronic opiate usage, whether prescribed or illicit, has been associated with changes in bone 
mass and is a recognized risk factor for the development of osteoporosis; however, the 
mechanism behind this effect is unknown. Here we show that lack of dynorphin, an 
endogenous opioid, in mice (Dyn−/−), resulted in a significantly elevated cancellous bone 
volume associated with greater mineral apposition rate and increased resorption indices. A 
similar anabolic phenotype was evident in bone of mice lacking dynorphin’s cognate receptor, 
the kappa opioid receptor. Lack of opioid receptor expression in primary osteoblastic cultures 
and no change in bone cell function after dynorphin agonist treatment in vitro indicates an 
indirect mode of action. Consistent with a hypothalamic action, central dynorphin signaling 
induces extracellular signal-regulated kinase (ERK) phosphorylation and c-fos activation of 
neurons in the arcuate nucleus of the hypothalamus (Arc). Importantly, this signaling also 
leads to an increase in Arc NPY mRNA expression, a change known to decrease bone 
formation. Further implicating NPY in the skeletal effects of dynorphin, Dyn−/−/NPY−/− 
double mutant mice showed comparable increases in bone formation to single mutant mice, 
suggesting that dynorphin acts upstream of NPY signaling to control bone formation. Thus the 
dynorphin system, acting via NPY, may represent a pathway by which higher processes 
including stress, reward/addiction and depression influence skeletal metabolism. Moreover, 
understanding of these unique interactions may enable modulation of the adverse effects of 
exogenous opioid treatment without directly affecting analgesic responses. 
 
 
1. Introduction 	  
The opioid family is complex, consisting of more than 20 peptides derived from three 
independent genes, proopiomelanocortin (POMC), proenkephalin (PENK), and prodynorphin 
(PDyn) (Boer and Van Minnen, 1985). These genes produce inactive polypeptide precursors 
that are activated following tissue-specific processing. In the case of the prodynorphin 
precursor, processing produces six dynorphins: dynorphin A, dynorphin B, alpha- and beta- 
neoendorphin, leumorphine and big dynorphin (Han and xie, 1982). Dynorphin is produced 
almost exclusively in the CNS, including the hypothalamus (Lin et al., 2006). 
Pharmacologically, dynorphins preferentially bind to the kappa-opioid receptor (KOR), but 
they also bind with reduced affinity to mu-opioid receptors (MOR) and delta-opioid receptors 
(DOR) (Mansour et al., 1995). While opiate analgesia is the result of activation of MOR 
signaling (Matthes et al., 1996), both dynorphin and KOR expression are elevated by chronic 
opiate exposure (Wang et al., 1999) indicating that chronic opiate use may involve responses 
from multiple opioid receptors, including the dynorphin/KOR system. 
 Opioids are critical agents for pain management but chronic use is associated with 
adverse side effects including an increased risk for the development of osteoporosis, affecting 
people of all ages, not just the elderly (Daniell et al., 2006 and Shorr et al., 1992). Several 
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mechanisms have been proposed to explain the increase in fracture evident following opiate 
exposure. In men, opiates may induce androgen deficiency, due to inhibition of 
gonoadotrophin release from the hypothalamus and subsequent reduction of testosterone 
synthesis (Daniell et al., 2006). A recent study in people with an average duration of 2.5 years 
opiate treatment for non-malignant pain found clinically significant hypogonadism in over 25% 
of men. Of these hypogonadal men, 50% had bone mass in the osteopenic or osteoporotic 
range (Fortin et al., 2008). However, central opioid effects on gonadal steroid production is 
not the only factor contributing to bone loss, as the same study found 42% of men had a 
testosterone level that was in the normal range but were osteopenic or osteoporotic. In 
women, a large cohort study of elderly individuals using opiates for pain management 
reported the age-adjusted risk of fracture was elevated for any non-spine (HR 1.76) and hip 
(HR 2.12) fracture (Ensrud et al., 2003). These associations were still evident following 
adjustment for potential confounders including dizziness, gait speed, cognitive function and 
femoral neck bone mineral density (BMD), further indicating a unique opiate effect on bone. 
These findings are also consistent with a case-control study (Shorr et al., 1992), which 
reported a 1.6-fold increase in the risk of hip fracture among current users of opioid 
analgesics, and a prospective cohort study which found a 2-fold risk of hip fracture in users of 
opioid analgesics (Guo et al., 1998). Indeed, opiate-associated osteoporosis is now 
sufficiently recognized that routine bone density screening is being proposed for those on 
chronic opiate treatment for pain (Fortin et al., 2008). Despite this growing concern, the 
mechanism behind opiate-induced osteoporosis remains poorly defined. 
 Interestingly, mouse models have shown that loss of dynorphin signaling reduces 
neuropeptide Y (NPY) expression in the arcuate nucleus of the hypothalamus (Arc) 
(Sainsbury et al., 2007 and Wittmann et al., 2009). Importantly, alterations in hypothalamic 
NPY, acting through the Arc, have previously been demonstrated to exert powerful effects 
upon bone mass and osteoblast activity. Arcuate-specific elevation of NPY expression 
induces marked reduction in osteoblast activity (Baldock et al., 2005) and acted to correct the 
increased bone mass following germline NPY ablation (Baldock et al., 2009). The relationship 
between opioid signaling and NPY was clearly demonstrated in feeding studies with NPY-
induced feeding being dose-dependently reduced by pretreatment with kappa opioid receptor 
antagonist or kappa antisense probes (Israel et al., 2005), demonstrating the downstream 
actions of dynorphin signaling in mediating NPY effects on feeding. A similar interaction 
between dynorphin and NPY has been demonstrated in other brain regions, with over 50% of 
NPY-ergic neurons in some hippocampal regions expressing the dynorphin-specific kappa 
opioid receptor (Racz and halasy, 2002). In light of these findings, we hypothesized that the 
opiate system, acting through dynorphin, may mediate its effect on bone through a central 
circuit involving the NPY pathway. To investigate this we generated a series of transgenic 
mouse models and studied their effects on bone homeostasis in vivo and in vivo. 
 
2. Materials and methods 
 
2.1. Animals 
Dynorphin knockout mice (Dyn−/−) and neuropeptide Y knockout mice (NPY−/−) were 
generated and maintained as previously published (Loacker et al., 2007 and Karl et al., 
2008). The dynorphin knockout leads to deletion of the entire prodynorphin gene including the 
initiation start codon, thereby eliminating all six potential dynorphin peptides. Double 
(Dyn−/−NPY−/−) knockout mice were generated by crossing Dyn and NPY single knockout 
mice and subsequently crossing of the double heterozygous mice. Bone tissue from KOR−/− 
mice (Simonin et al., 1998) were kindly provided by Prof. Kieffer, University of Strasbourg. 
Littermate controls were used where possible. Mice were fed a normal chow diet ad libitum 
(6% calories from fat, 21% calories from protein, 71% calories from carbohydrate, 2.6 kcal/g; 
Gordon’s Specialty Stock Feeds, Yanderra, New South Wales, Australia). All research and 
animal care procedures were approved by the Garvan Institute/St. Vincent’s Hospital Animal 
Experimentation Ethics Committee and were in agreement with the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purpose. Mice were housed under 
conditions of controlled temperature (22 °C) and illumination (12-h light, 12-h dark cycle, 
lights on at 0700 h). 
 
2.2. Statistical analyses 
Values are presented as mean ± standard error (SEM), and statistical comparisons were 
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made using a two-tailed student’s t-test, or one-way ANOVA and Bonferroni post hoc tests 
when an overall significant difference was detected. p values <0.05 were considered 
statistically significant. 
 
2.3. Analysis of body composition 
Mice were anesthesised with 100 mg/kg ketamine and 20 mg/kg xylazine (Parke Davis-Pfizer, 
Sydney, Australia; and Bayer, Leverkusen, Germany) and then scanned for whole body bone 
mineral density (BMD) and bone mineral content (BMC), lean mass, fat mass and percentage 
of fat using dual energy X-ray absorptiometry (DXA), (Lunar PIXImus2 mouse densitometer; 
GE Healthcare, WI). Following cull by cervical dislocation and decapitation, isolated femoral 
scans were conducted on defleshed femurs. 
 
2.4. Bone histomorphometry 
Mice were injected with the fluorophor calcein (Sigma Chemical Company, St. Louis, USA) at 
20 mg/kg (s.c.), 10 and 3 days prior to collection. Mice were killed by cervical dislocation 
between 10.00–14.00 h for tissue collection. Both femora and the lumbar spine were excised 
and fixed in 4% paraformaldehyde for 16 h at 4 °C. The right femur was bisected transversely 
at the midpoint of the long axis and the distal half embedded undecalcified in ethacrylate resin 
(Medim-Medizinische Diagnostik, Giessen, Germany). Sagittal sections with 5 µm thickness 
were analysed for osteoblastic and osteoclastic parameters, as previously described (Allison 
et al., 2006, Lundberg et al., 2007a and Lundberg et al., 2007b. 
 
2.5. Micro-computed tomography 
Femurs and third lumbar vertebra (L3) were assessed using micro-computed tomography 
(micro-CT) as described before (Baldock et al., 2009). Briefly, following fixation, left femora 
were cleaned of muscle and placed in a Skyscan 1174 (Skyscan, Aartselaar, Belgium). The 
X-ray source was set at 50 kV and 800 µA, with a 0.5 mm aluminium filter and sharpening 
was set to 40%. Image projections were acquired over an angular range of 180° (angular step 
of 0.4°) with pixel size of 6.2 µm and the exposure set to 3600 ms. The image slices were 
reconstructed using NRecon, which uses a modified Feldkamp algorithm (Skyscan, 
Aartselaar, Belgium). In vivo micro-CT scans of the third lumbar vertebra (L3) were obtained 
with the same manner; with the region of interest extending 20 slices from either growth plate. 
 
2.6. Isolation and differentiation of bone marrow stromal cells 
The isolation and differentiation of plastic adherent bone marrow stromal cells (BMSCs) from 
5 to 9 week old mice was carried out as previously described (Lundberg et al., 2007b). 
 Differentiation into mineral-producing osteoblasts was achieved by culturing the cells 
in osteogenic media consisting of control media supplemented with 50 mg/L ascorbic acid 
and 10 mM ß-glycerophosphate. Alkaline phosphatase activity (ALP), a marker for early 
osteoblast differentiation, was visualized by ALP staining. Briefly, ALP activity in cells was 
detected using p-nitrophenylphosphate (pNPP) (Sigma–Aldrich, St. Louis, MO, USA) as the 
substrate. Mineralization of calcium deposits was assessed by von Kossa staining (2% silver 
nitrate staining under UV light for 30 min at room temperature), followed by multiple washes 
with distilled water to remove background staining (Lee et al., 2011). The extent of ALP 
staining or mineralisation was quantified using the Leica QWin imaging system (Leica Micro-
systems, Heerbrugg, Switzerland). All samples were assayed in triplicate. Results are 
representative of a minimum of two independent experiments. 
 
2.7. Isolation of calvarial osteoblastic cells 
Primary calvarial osteoblasts were isolated as previously described (Jochum et al., 2000). 
Briefly, five calvaria from six-day-old mice were dissected, cleaned in 70% ethanol then PBS. 
Calvaria were then digested using 0.1% Collagenase and 0.2% Dispase II α-MEM without 
FCS and were shaken for 10 min at 37 °C. After incubation the upper liquid phase, (fraction 1) 
was discarded. This step was repeated by adding 1 ml of digestion medium, but the liquid 
phase (fraction 2) was recovered and collected. This step was repeated four times. The cells 
from fractions 2–5 were pooled by centrifugation (5 min, 500 g). The supernatant was 
discarded and the pellet was resuspended in 1 ml α-MEM. The cells were seeded and 
cultured in 6-well plates. 1.5 ml of α-MEM culture medium containing 10% FCS and 
antibiotics was added to each well before 1 ml of cell suspension was added and grown at 
37 °C in an atmosphere of 5% CO2 in air. The medium was replaced every 3 days and the 
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cells were grown until sub-confluent before expanded and final use. 
 
2.8. Isolation of neuronal cells 
Pregnant female C57Bl/6 mice were imported from the Animal Resources Centre (Perth, 
Australia). Briefly, cerebra taken from P1-P2 pups were macerated, trypsinized (0.5% trypsin, 
10 min, 37 °C/5% CO2) and triturated. The cell suspension was washed in culture media 
(DMEM/F12 with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 100 U/ml penicillin, 
100 mg/ml streptomycin) and cultured at 37 °C/5% CO2 in poly-d-lysine (10 mg/ml in borate 
buffer)-coated 75 cm2 tissue-culture flasks. The media was changed once a week. At 10–
14 days in vitro the mixed glial cultures were plated and used for cell signaling experiments. 
 
2.9. RNA extraction, cDNA preparation, and RT-PCR 
Marrow-intact femurs and tibias (Bo), calvaria (Ca), white adipose tissue (Ad) and whole brain 
(Br) were isolated from 6–10 week old mice and snap frozen. Subsequently the selected 
tissue was homogenized in TRIzol® reagent using a polytron. RNA extractions were carried 
out using TRIzol® reagent according to the manufacturer’s instructions (Invitrogen). 
 Amplification of Dynorphin (DYN)/kappa-opioid receptor (KOR)/mu-opioid receptor 
(MOR) and delta-opioid receptor (DOR) PCR: initial denaturation, 94 °C, 5 min @ 35 cycles of 
PCR amplification: denaturation, 94 °C for 40 s, annealing 57 °C for 40 s, elongation, 72 °C 
for 45 s and final elongation, 72 °C, 15 min, cool off, 4 °C. 
Primers: DYN-F ATGTTATGGCGGACTGCCTG, DYN-R TTTGTACAGGT CCTCATGCC; 
product 548 bp. KOR-F CCTGCTCTCCCAGTGCTTGC KOR-R 
GGTGCCTCCAAGGACTATCG; product 535 bp. DOR-F CTGTCTGCCATCCT GTCAAA, 
DOR-R CGATGACGGAAGATGTGGATG; product 402 bp. MOR-F 
CCTCTCTTCTGCCATTGGTC, MOR-R GAGGAAGTTGGGATGCAGAA; product 489 bp. 
 
2.10. Stimulation protein extraction and Western blotting 
Primary calvarial cells were serum starved over night (0.5% FBS) and treated with 100 nM 
kappa-opioid receptor agonist U-50,488 (Sigma–Aldrich, Sydney, NSW, Australia) for the 
indicated time periods. 
 Protein extracts were prepared as previously described (David et al., 2002). Protein 
concentrations were measured using Bradford (Sigma–Aldrich, Sydney, NSW, Australia). 
Proteins were electrophoresed on 10% SDS polyacrylamide gels and transferred to 
nitrocellulose membrane. The blots were probed with p44/42 MAPK (Erk1/2) antibody (Cell 
Signalling Technology). As a secondary antibody, anti-mouse/rabbit IgG HRP conjugate 
(Promega, Sydney, NSW, Australia) was used. Bands were detected by ECL (GE Healthcare 
Australia, Sydney, NSW, Australia). 
 
2.11. Central agonist injection and c-fos immunohistochemistry 
Wild type mice at 12 weeks of age were injected intracerebroventricularly (icv) with either 
1.5 µl kappa opioid receptor agonist U-50,488 (10 µM) or control buffer at 10:00–12:00 h. 
Brain injection coordinates relative to Bregma were posterior 0.34 mm, lateral ±1.0 mm, 
ventral 2.5 mm, corresponding to the left lateral ventricle (Franklin and paxinos, 1997). To 
ensure the least possible variation in c-fos expression, all mice were sacrificed 60 ± 1 min 
after icv injection. C-fos immunohistochemistry was performed on free-floating sections as 
described previous (Lin et al., 2009). Comparisons were made between the two groups (three 
mice per group) stained at same time and the average number of neuron counts in each 
nucleus was determined from both left and right sides. All groups were pooled for final 
analysis and the differences between groups were assessed by ANOVA followed by 
Bonferroni post hoc tests. 
 
2.12. Intrahypothalamic injection into mouse Arc and in situ hybridization 
Twelve wild type mice at 15 weeks of age were divided into four groups and anesthetized with 
100 and 20 mg/kg ketamine/xylazine (Parke Davis-Pfizer, Sydney, Australia and Bayer AG, 
Leverkusen, Germany) and placed on a Kopf stereotaxic frame (David Kopf, California, USA), 
with the head in the flat skull position. Mice were injected unilaterally into the arcuate 
hypothalamic nucleus (Arc) with 1 µl Kappa (U-50,488) (10 µM), 1 µl Mu (DAMGO) (1 mM), 
1 µl Delta opioid (DPDPE) (10 mM) receptor agonists (Sigma, USA) or 1 µl PBS as control, 
respectively, using a 10 µl Hamilton syringe attached to Micro4 Micro Syringe Pump 
Controller (World Precision Instruments Inc., Sarasota, USA). Brain injection coordinates 
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relative to Bregma were posterior 1.94 mm, lateral ± 0.3 mm, ventral 5.6 mm, corresponding 
to the Arc. 
 All mice were culled by cervical dislocation and decapitation exactly 60 min after 
injection and brains were removed and immediately frozen on dry ice. Coronal sections 
(20 µm) were cut on a cryostat and thaw-mounted on Superfrost® slides (Menzel-Glaser, 
Braunschweig, Germany). Matching sections from the same coronal brain level of three 
opioid receptor agonists injection and PBS injection of mice (n = 3 mice/group) were assayed 
together using radiolabelled DNA oligonucleotides complementary to mouse NPY (5′-
GAGGGTCAGTCCACACAGCCCCATTCGCTTGTTACCTAGCAT-3′); as described 
previously ( Lin et al., 2006). 
 For evaluation of mRNA levels in scattered neurons, images from dipped sections 
were digitized using a ProgRes 3008 camera (Zeiss, Jena, Germany) mounted on a Zeiss 
Axiophot microscope (Zeiss, Jena, Germany). Silver grain density over single neurons was 
evaluated using NIH-Image 1.61 software (written by Wayne Rasband and available from 
anonymous FTP at zippy.nimh.nih.gov). Background labeling was uniform and never 
exceeded 5% of specific signal. 
 
3. Results 
 
3.1. Increased bone mass and reduced fat mass in mice lacking dynorphin expression 
In order to determine a possible role for dynorphin signaling in skeletal regulation, body 
composition and bone content were analyzed by DXA in 16-week-old male and female wild 
type (WT) and Dyn−/− mice. Loss of dynorphin significantly reduced body weight, lean mass 
(in females only), total fat mass and percent adiposity without change in stature, as 
represented by femur length (Table 1). In contrast to the loss of weight, femoral bone mineral 
density (BMD) and bone mineral content (BMC) were greater in both sexes of Dyn−/− mice, 
with this change also evident in whole body BMD and whole body BMC in male mice (Table 
1). 
	  	   	  	  
3.2. Loss of dynorphin signaling increases cancellous bone volume and turnover 
To define the cellular changes responsible for the altered bone mass, cancellous bone of the 
distal femoral metaphysis was examined. In Dyn−/− mice, cancellous bone volume was 
agonists (Sigma, USA) or 1 ll PBS as control, respectively, using a
10 ll Hamilton syringe attached to Micro4 Micro Syringe Pump
Controller (World Precision Instruments Inc., Sarasota, USA). Brain
injection coordinates relative to Bregma were posterior 1.94 mm,
lateral ± 0.3 mm, ventral 5.6 mm, corresponding to the Arc.
All mice were culled by cervical dislocation and decapitation
exactly 60 min after injection and brains were removed and imme-
diately frozen on dry ice. Coronal sections (20 lm) were cut on a
cryostat and thaw-mounted on Superfrost! slides (Menzel-Glaser,
Braunschweig, Germany). Matching sections from the same coro-
nal brain level of three opioid receptor agonists injection and PBS
injection of mice (n = 3 mice/group) were assayed together using
radiolabelled DNA oligonucleotides complementary to mouse NPY
(50-GAGGGTCAGTCCACACAGCCCCATTCGCTTGTTACCTAGCAT-30);
as described previously (Lin et al., 2006).
For evaluation of mRNA levels in scattered neurons, images
from dipped sections were digitized using a ProgRes 3008 camera
(Zeiss, Jena, Germany) mounted on a Zeiss Axiophot microscope
(Zeiss, Jena, Germany). Silver grain density over single neurons
was evaluated using NIH-Image 1.61 software (written by Wayne
Rasband and available from anonymous FTP at zippy.nimh.nih.-
gov). Background labeling was uniform and never exceeded 5% of
specific signal.
3. Results
3.1. Increased bone mass and reduced fat mass in mice lacking
dynorphin expression
In order to determine a possible role for dynorphin signaling in
skeletal regulation, body composition and bone content were ana-
lyzed by DXA in 16-week-old male and female wild type (WT) and
Dyn!/! mice. Loss of dynorphin significantly reduced body
weight, lean mass (in females only), total fat mass and percent adi-
posity without change in stature, as represented by femur length
(Table 1). In contrast to the loss of weight, femoral bone mineral
density (BMD) and bone mineral content (BMC) were greater in
both sexes of Dyn!/!mice, with this change also evident in whole
body BMD and whole body BMC in male mice (Table 1).
3.2. Loss of dynorphin signaling increases cancellous bone volume and
turnover
To define the cellular changes responsible for the altered bone
mass, cancellous bone of the distal femoral metaphysis was exam-
ined. In Dyn!/! mice, cancellous bone volume was significantly
increased (males 33% and females 45%), associated with increased
trabecular number and trabecular thickness in both sexes (Fig. 1A–
D) The greater bone volume was consistent with an increase in
bone formation rate (Fig. 1E) resulting from changes in the speed
of bone formation. Indeed, mineral apposition rate was an average
of 45% greater than wild type, with no change in mineralising sur-
face (Fig. 1F and G). The change in mineral apposition rate is evi-
dent in the photomicrographs (Fig. 1H). In addition, bone
resorption indices were also elevated, indicating an increase in
bone turnover in Dyn!/! mice. Specifically, osteoclast surface
and osteoclast number were increased on average by 60% and
70%, respectively in both sexes (Fig. 1I and J). Greater bone mass
in Dyn!/! mice was also evident in cortical bone, with femoral
cortical area and thickness increased compared to WT (Fig. 1K–
M), with a coincident increase in calculated bone strength as indi-
cated by the significant increase in polar moment of inertia
(Fig. 1N)
3.3. Kappa opioid receptor deletion recapitulates the dynorphin null
anabolic phenotype
To assess whether dynorphin regulates bone homeostasis via
signaling through its preferred kappa opioid receptor (KOR), mice
genetically deficient in KOR were analyzed for changes in bone
homeostasis. In KOR!/!mice, cancellous bone volume was signif-
icantly increased, associated with increased trabecular number and
trabecular thickness in both sexes (Fig. 2A–D,O–Q) The greater
bone volume was consistent with an increase in bone formation
rate (Fig. 2E) resulting from greater mineral apposition, with no
change in mineralising surface (Fig. 2F and G). The change in min-
eral apposition rate is evident in the photomicrographs (Fig. 2H). In
contrast to Dyn!/!mice, bone resorption indices were not altered
in KOR!/! (Fig. 2I and J). Consistent with the photomicrographs of
KOR!/!mid femoral cross-sections (Fig. 1K), DXA analysis of fem-
oral BMD indicated a significant increase in female mice (Fig. 1P).
Both male and female KOR!/! mice exhibited a strong trend for
increased femoral BMC (p = 0.08, p = 0.09, respectively) (Fig. 1Q).
Thus opioid signaling through the dynorphin family of peptides,
acts to tonically reduce bone formation.
3.4. Dynorphin does not act directly upon osteoblasts
As clearly demonstrated above, dynorphin signaling is required
for normal bone homeostasis; however, the mechanism by which
this opioid family alters bone cell activity is unclear. In order to de-
fine the signaling pathway by which dynorphins alter bone cell
activity, we first investigated the presence of dynorphin and opioid
receptor expression in bone tissue. As shown in Fig. 2A, skeletal tis-
sues: whole bone (marrow included) (Bo) and calvarial tissue (Ca),
as well as adipose tissue, exhibit no dynorphin or kappa opioid
receptor expression. Indeed no expression of any of the three
opioid receptors was evident in bone, with low levels of delta
receptor evident in fat tissue (Fig. 3A). In contrast, dynorphin and
all the opioid receptors were strongly expressed in brain tissue.
Table 1
Body composition and bone mass in Dyn!/! mice.
Characteristics WT male (n > 15) Dyn!/!male
(n > 15)
p
Body weight (g) 30.71 ± 1.15 28.14 ± 0.51 ⁄
Lean mass (g) 22.41 ± 0.74 22.41 ± 0.58 NS
Fat mass (g) 5.48 ± 0.52 3.25 ± 0.13 ⁄⁄⁄
Adiposity (% of BW) 19.55 ± 1.40 13.14 ± 0.98 ⁄⁄⁄
Isolated femur length (mm) 16.04 ± 0.14 16.11 ± 0.16 NS
Whole body BMD (mg/
mm2)
52.36 ± 0.07 57.18 ± 0.09 ⁄⁄
Whole body BMC (mg) 377.30 ± 1.24 431.30 ± 1.02 ⁄⁄
Isolated femur BMD (mg/
mm2)
61.01 ± 1.26 72.25 ± 1.84 ⁄⁄⁄
Isolated femur BMC (mg) 25.33 ± 0.14 30.63 ± 0.11 ⁄
WTfemale(n > 15) Dyn!/
!female(n > 15)
Body weight (g) 22.83 ± 0.61 20.15 ± 0.29 ⁄⁄⁄
Lean mass (g) 17.04 ± 0.44 15.08 ± 0.22 ⁄⁄⁄
Fat mass (g) 4.36 ± 0.26 2.99 ± 0.13 ⁄⁄⁄
Adiposity (% of BW) 20.33 ± 1.01 16.54 ± 0.62 ⁄⁄
Isolated femur length (mm) 15.84 ± 0.11 15.64 ± 0.13 NS
Whole body BMD (mg/
mm2)
52.55 ± 0.06 51.00 ± 0.07 NS
Whole body BMC (mg) 339.10 ± 0.82 336.90 ± 0.83 NS
Isolated femur BMD (mg/
mm2)
53.12 ± 1.10 59.14 ± 1.51 ⁄⁄
Isolated femur BMC (mg) 19.80 ± 0.07 23.50 ± 0.12 ⁄
* p < 0.05.
** p < 0.01.
*** p < 0.0001.
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significantly increased (males 33% and females 45%), associated with increased trabecular 
number and trabecular thickness in both sexes (Fig. 1A–D) The greater bone volume was 
consistent with an increase in bone formation rate (Fig. 1E) resulting from changes in the 
speed of bone formation. Indeed, mineral apposition rate was an average of 45% greater than 
wild type, with no change in mineralising surface (Fig. 1F and G). The change in mineral 
apposition rate is evident in the photomicrographs (Fig. 1H). In addition, bone resorption 
indices were also elevated, indicating an increase in bone turnover in Dyn−/− mice. 
Specifically, osteoclast surface and osteoclast number were increased on average by 60% 
and 70%, respectively in both sexes (Fig. 1I and J). Greater bone mass in Dyn−/− mice was 
also evident in cortical bone, with femoral cortical area and thickness increased compared to 
WT (Fig. 1K–M), with a coincident increase in calculated bone strength as indicated by the 
significant increase in polar moment of inertia (Fig. 1N) 
 
	  
3.3. Kappa opioid receptor deletion recapitulates the dynorphin null anabolic phenotype 
To assess whether dynorphin regulates bone homeostasis via signaling through its preferred 
kappa opioid receptor (KOR), mice genetically deficient in KOR were analyzed for changes in 
bone homeostasis. In KOR−/− mice, cancellous bone volume was significantly increased, 
associated with increased trabecular number and trabecular thickness in both sexes (Fig. 2A–
D,O–Q) The greater bone volume was consistent with an increase in bone formation rate 
(Fig. 2E) resulting from greater mineral apposition, with no change in mineralising surface 
Interestingly, loss of dynorphin expression results in slightly
increased expression levels of mu-opioid receptors in the brain
and adipose tissue (Fig. 3A), but importantly does ot alter
expression patterns in skeletal tissue. Moreover, dynorphin and
KOR expression are also absent from BMSC cultures from WT and
Dyn!/! mice, and were not induced by FCS or NPY in serum-
starved wild type cultures (Fig. 3B).
To further exclude the possibility of a direct action of dyn r-
phin and KOR receptor signaling, we treated mouse primary oste-
oblasts and primary neuronal cells with U-50,488, a KOR-specific
agonist (Simonin et al., 1998), and compared P-ERK activation.
Consistent with kappa opioid receptor expression, sustained acti-
vation of P-ERK is evident in neuronal cells, however activation of
ERK phosphorylation was virtually absent in osteoblastic cells
(Fig. 3C). In addition, we also investigated the effect of dynorphin
deficiency on osteogenic proliferation and differentiation by
assessing the ability of primary calvarial osteoblastic cultures
isolated from Dyn!/! mice to differentiate into mature,
mineral-producing osteobl sts in vitro. There was no difference
in proliferation efficiency between the Dyn!/! and control cul-
tures (Fig. 3D). Differentiation, following plating in osteogenic
media, was assessed by alkaline phosphatase production and
mineralization, which were not different between WT and
Dyn!/! cultures as v dent by the photomicrographs (Fig. 3E
and F). Taken together, these results strongly suggest that
dynorphin’s effect on bone does not involve a direct action on
osteoblast, but rather involve an indirect pathway.
3.5. Dynorphin regulates NPY expression via kappa opioid action
As direct action of dynorphin on bone tissue does not seem to
explain the altered bone phenotype in Dyn!/! mice, we focused
Fig. 1. Skeletal phenotype of Dyn!/!mice. (A) Photomicrographs of the distal femur of 16-week-old male wild type (WT) and dynorphin knockout (Dyn!/!) mice showing
more abundant darkly stained bone in the mutant mice. (B–D) Analysis of cancellous bone in male and female WT and Dyn!/!mice revealed increased bone volume in the
knockouts (B) due to greater trabecular number (C) and thickness (D). (E–G) Bone formation rate (E) was greater in Dyn!/! than in WT mice due to increased mineral
apposition rate (F), with no change in mineralizing surface (G). (H) Photomicrographs showing altered mineral apposition rate in Dyn!/! versus WT mice. (I and J) Bone
resorption indices were also elevated in Dyn!/! compared to WT mice, with greater osteoclast surface (I) and osteoclast number (J) in the knockouts. Data are means ± SEM
of 3–15 mice per group. ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.0001 versus WT (K–N) Cortical bone was similarly increased in Dyn!/!mice. (K) Micro-computed tomography analysis
of the mid-femoral cross-section of male mice, showed greater cortical bone area (L) and cortical thickness (M) resulting in greater calculated bending strength (N). Data are
means ± SEM of 6–7 mice per group. ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.0001 versus WT.
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(Fig. 2F and G). The change in mineral apposition rate is evident in the photomicrographs 
(Fig. 2H). In contrast to Dyn−/− mice, bone resorption indices were not altered in KOR−/− 
(Fig. 2I and J). Consistent with the photomicrographs of KOR−/− mid femoral cross-sections 
(Fig. 1K), DXA analysis of femoral BMD indicated a significant increase in female mice (Fig. 
1P). Both male and female KOR−/− mice exhibited a strong trend for increased femoral BMC 
(p = 0.08, p = 0.09, respectively) (Fig. 1Q). Thus opioid signaling through the dynorphin family 
of peptides, acts to tonically reduce bone formation. 
 
 
	  	  
3.4. Dynorphin does not act directly upon osteoblasts 
As clearly demonstrated above, dynorphin signaling is required for normal bone homeostasis; 
however, the mechanism by which this opioid family alters bone cell activity is unclear. In 
order to define the signaling pathway by which dynorphins alter bone cell activity, we first 
investigated the presence of dynorphin and opioid receptor expression in bone tissue. As 
shown in Fig. 2A, skeletal tissues: whole bone (marrow included) (Bo) and calvarial tissue 
(Ca), as well as adipose tissue, exhibit no dynorphin or kappa opioid receptor expression. 
Indeed no expression of any of the three opioid receptors was evident in bone, with low levels 
of delta receptor evident in fat tissue (Fig. 3A). In contrast, dynorphin and all the opioid 
our attention on potential indirect mechanisms via the central
nervous system. To test this we injected kappa opioid agonist
U-50,488 icv into mouse brains nd ev luated the activatio of
neurons indicated by c-fos activity (Fig. 4A). KOR agonist injection
induced a strong and specific activation of neurons in the Arc of the
hypothalamus, with 37 ± 6 positive staining neurons in the Arc of
agonist-inj cted mice compared to 10 ± 2 in the Arc of control-
injected mice; (n = 3, p = 0.003).
We have shown previously that lack of dynorphin signaling
leads to reduced expression of neuropeptide Y in the Arc (Sainsbury
et al., 2007; Wittmann et al., 2009), which would be expected to
result in a NPY-induced increase in bone mas and provide a
mechanism for dynorphins action on bone (Baldock et al., 2005,
2009, 2002, 2006). In order to test this hypothesis we injected
KOR (U-50,488), DOR (DPDPE) andMOR (DAMGO) recep or-specific
agonists unilaterally into the arcuate nucleus of wild type mice
and measured changes in NPY mRNA expression by in situ
hybridization between injected and contralateral sides of the Arc.
Interestingly, silver grain density ver single neurons on the
injected side of the Arc was significantly increased 2.8-fold in mice
injected with the Kappa opioid receptor agonist (1143 ± 201)
compared to the intra-hypothalamic contra lateral Arc control side
(402 ± 49), (n = 3; p < 0.005); (Fig. 3C). Importantly, no significant
changes were fou d in the Arc of mu and delta opioid receptor
Fig. 2. Skeletal phenotype of KOR!/!mice. (Q) Kappa opioid receptor knockout mice display increased bone mass. The skeletal phenotype of KOR!/!mice recapitulates the
anabolic changes in dynorphin knockout. (A) Photomicrographs of the distal femur of 16-week-old male wild type (WT) and kappa opioid receptor knockout (KOR!/!) mice
showing more abundant darkly stained bone in the mutant mice. (B–D) Analysis of cancellous bone in male and femaleWT and KOR!/!mice revealed increased bone volume
in the knockouts (B) due to greater trabecular number (C) and thickness (D). (E–G) Bone formation rate (E) was greater in KOR!/! than in WT mice due to increased mineral
apposition rate (F), with no change in mineralizing surface (G). (H) Photomicrographs showing altered mineral apposition rate in KOR!/! versus WT mice. (I and J) Bone
resorption indices were not elevated in KOR!/! compared to WTmice, with greater osteoclast surface (I) and osteoclast number (J) in the knockouts. (K–N) Cortical bone was
similarly increased in KOR!/!mice. (K) Micro-computed tomography analysis of the mid-femoral cross-section of male mice. Femoral bone mineral density (BMD) as greater
in female KOR!/! mice (L), with a consistent trend for increased (M) femoral bone mineral content (BMC) in male and female KOR!/! mice versus WT (p = 0.08, p = 0.09,
respectively). Data are means ± SEM of 4 mice per group. ⁄p < 0.05, ⁄⁄p < 0.01 versus WT.
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receptors were strongly expressed in brain tissue. Interestingly, loss of dynorphin expression 
results in slightly increased expression levels of mu-opioid receptors in the brain and adipose 
tissue (Fig. 3A), but importantly does not alter expression patterns in skeletal tissue. 
Moreover, dynorphin and KOR expression are also absent from BMSC cultures from WT and 
Dyn−/− mice, and were not induced by FCS or NPY in serum-starved wild type cultures (Fig. 
3B). 
 
	  
 To further exclude the possibility of a direct action of dynorphin and KOR receptor 
signaling, we treated mouse primary osteoblasts and primary neuronal cells with U-50,488, a 
KOR-specific agonist (Simonin et al., 1998), and compared P-ERK activation. Consistent with 
agonist (Fig. 4D and E) or saline injected control groups. This cle rly
indicates that dynorphin signaling through its preferred kappa
receptor increases NPY expression, which has b en shown to result
in decreased bone formation (Baldock et al., 2002, 2005, 2006)
Fig. 3. No direct effects of dynorphin on bone cells. (A) Expression for dynorphin (DYN) and all three opioid receptors (kappa, KOR; mu, MOR; and delta, DOR) was present in
samples of brain tissue (Br) fromWTmice, but was absent fromwhole bone (Bo) and calvarial tissue (Ca) fromWTs. WT white adipose tissue (Ad) showed expression for DOR
only. Tissues from Dyn!/! mice recapitulated these WT expression patterns, with MOR as well as DOR evident in white adipose tissue, and a lack of DYN in brain. (B) DYN
and KOR were absent from bone marrow stromal cell cultures (BMSC) and could not be induced in starved cells by addition of fetal calf serum (FCS) or neuropeptide Y (NPY)
in primary calvarial osteoblasts. (C) The kappa agonist U-50,488 induced signaling in neuronal cells via rapid phosphorylation of ERK, but not in calvarial osteoblasts. (D)
Proliferation of primary osteoblastic cultures was not different between WT and Dyn!/! cells. (E and F) Differentiation is not altered in Dyn!/! cells, as indicated by the
observation that alkaline phosphatase (E) and mineralization (F) were similar in primary osteoblast cultures from WT and Dyn!/! mice.
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kappa opioid receptor expression, sustained activation of P-ERK is evident in neuronal cells, 
however activation of ERK phosphorylation was virtually absent in osteoblastic cells (Fig. 3C). 
In addition, we also investigated the effect of dynorphin deficiency on osteogenic proliferation 
and differentiation by assessing the ability of primary calvarial osteoblastic cultures isolated 
from Dyn−/− mice to differentiate into mature, mineral-producing osteoblasts in vitro. There 
was no difference in proliferation efficiency between the Dyn−/− and control cultures ( Fig. 
3D). Differentiation, following plating in osteogenic media, was assessed by alkaline 
phosphatase production and mineralization, which were not different between WT and 
Dyn−/− cultures as evident by the photomicrographs (Fig. 3E and F). Taken together, these 
results strongly suggest that dynorphin’s effect on bone does not involve a direct action on 
osteoblast, but rather involve an indirect pathway. 
 
3.5. Dynorphin regulates NPY expression via kappa opioid action 
As direct action of dynorphin on bone tissue does not seem to explain the altered bone 
phenotype in Dyn−/− mice, we focused our attention on potential indirect mechanisms via the 
central nervous system. To test this we injected kappa opioid agonist U-50,488 icv into 
mouse brains and evaluated the activation of neurons indicated by c-fos activity (Fig. 4A). 
KOR agonist injection induced a strong and specific activation of neurons in the Arc of the 
hypothalamus, with 37 ± 6 positive staining neurons in the Arc of agonist-injected mice 
compared to 10 ± 2 in the Arc of control-injected mice; (n = 3, p = 0.003). 
 
	  	  
 We have shown previously that lack of dynorphin signaling leads to reduced 
expression of neuropeptide Y in the Arc (Sainsbury et al., 2007 and Wittmann et al., 2009), 
which would be expected to result in a NPY-induced increase in bone mass and provide a 
mechanism for dynorphins action on bone (Baldock et al., 2005, Baldock et al., 2009, Baldock 
et al., 2002 and Baldock et al., 2006). In order to test this hypothesis we injected KOR (U-
50,488), DOR (DPDPE) and MOR (DAMGO) receptor-specific agonists unilaterally into the 
arcuate nucleus of wild type mice and measured changes in NPY mRNA expression by in situ 
hybridization between injected and contralateral sides of the Arc. Interestingly, silver grain 
density over single neurons on the injected side of the Arc was significantly increased 2.8-fold 
in mice injected with the Kappa opioid receptor agonist (1143 ± 201) compared to the intra-
hypothalamic contra lateral Arc control side (402 ± 49), (n = 3; p < 0.005); (Fig. 3C). 
Importantly, no significant changes were found in the Arc of mu and delta opioid receptor 
agonist (Fig. 4D and E) or saline injected control groups. This clearly indicates that dynorphin 
signaling through its preferred kappa receptor increases NPY expression, which has been 
3.6. Bone homeostasis following coincident loss of dynorphin and
neuropeptide Y signaling
The involvement of NPY-mediated processes in the skeletal
phenotype of Dy !/! mice was furt er explored by comparison
of Dyn!/! with NPY!/! mice and Dyn!/!NPY!/! double delete
mice. In the distal femoral metaphysis cancellous bone volume was
similarly elevated in Dyn!/! and NPY!/! mice (Fig. 5A). Impor-
tantly, Dyn!/!NPY!/!mice displayed equivalently increased can-
cellous bone volume, with no diff rence between the three mut nt
genotypes (Fig. 5B). Moreover, trab c lar number was similarly in-
creased in the mutant mice, consistent with equivalent increases in
mineral apposition rate (Fig. 5E). The increase in mineralizing sur-
face was not significant in NPY!/!mice, as a result bone formation
rate was only significantly elevated in Dyn!/! and Dyn!/!NPY!/
! models (Fig. 5F and G). Bone resorption ind ces were also simi-
larly altered, with greater osteoclast number and surface in the
three mutant groups compared to wild type mice (Fig. 5H and I).
In contrast, in lumbar vertebra, NPY!/! mice were the only group
to show a significant skeletal change. Critically, the similarity in
bone homeostasis between dynorphin and NPY deficiency provide
further evidence for a single pathway to bone.
4. Discussion
Discovery of the scope and strength of neural influences upon
skeletal tissue has been an important advance in bone biology in
recent years (Driessler and Baldock, 2010). Further expanding
these unique neuro/skeletal relationships, here we identify a no-
vel interaction between the opioid system and bone demonstrat-
ing an inhibitory action of dynorphins on skeletal tissue, acting
through kappa opioid receptors. In particular, loss of dynorphins,
one of the three endorphin ligand families, induces a skeleton-
wide increase in bone mass thereby revealing for the first time
a connection between opioid signaling and bone mass regulation.
Moreover, this increase in bone mass in dynorphin knockout
animals is most likely due to a lack of kappa-mediated stimula-
tion of hypothalamic neuropeptide Y expression. In this manner,
upregulation of dynorphin and kappa receptor expression, known
to occur in response to chronic opiate exposure (Wang et al.,
1999), may increase central NPY expression and – given the
known role of hypothalamic NPY expression to inhibit bone
(Baldock et al., 2009, 2002, 2006; Allison et al., 2006) – thereby
suppress bone formation and reduce bone mass and strength.
Importantly, inhibition of this pathway may enable attenuation
of the skeletal side-effects of chronic opiate exposure, without
modulation of the analgesic effects, which occur predominantly
through the mu-opioid receptor.
Dynorphin signaling has been implicated in numerous pro-
cesses including stress and depression, as well as epilepsy and en-
ergy homeostasis (Sainsbury et al., 2007; Schwarzer, 2009). The
cu rent tudy is the first to identify dynorphin actions in the regu-
lation of bone mass and provides a potential link to known opioid
side-effects on bone. Complete inhibition of dynorphin production
was associated with an increase in bone mass, in both male and fe-
male mice, with a significant increase in calculated bone strength.
This change was coincident with increased activity of both bone-
forming osteoblastic and bone-resorbing osteoclastic bone cell lin-
eages. Both bone formation and bone resorption were increased,
with osteoclasts being more common on bone surfaces in Dyn!/
! mice. Critically, bone formation was increased to a greater de-
gree than bone resorption, with increases in the rate at which
the bone mineral apposition process occurred, and resulting in a
net gain in bone mass.
Opioid signaling is complex, with numerous ligands acting
across several opioid receptors, and abundant expression in central
and peripheral nervous tissue. However, expression of dynorphin
and its cognate receptor, the kappa opioid receptor, were not de-
tected in primary osteoblastic cultures or whole bone extracts. This
result strongly suggested a non-local action of dynorphin on bone.
Several additional lines of evidence were consistent with this
hypothesis. Firstly, all opioid receptors and dynorphin were
Fig. 4. KOR agonist-specific changes in the hypothalamus. (A and B) ICV injection of the KOR specific agonist U-50,488 strongly increases c-fos activation of arcuate
hypothalamic (Arc) neurons (B) compared to control saline-injected mice (A). Bar represents 120 lm. (C) Unilateral Arc injection of the KOR-specific agonist U-50,488 results
in strong upregulation of NPY mRNA on the injected side but not on the contralateral control side. (D) Injection of either the MOR-specific agonist DAMGO or (E) the DOR-
specific agonist DPDPE have no effect on NPY mRNA expression in the Arc. n = 3, bar represents 60 lm.
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shown to result in decreased bone formation ( Baldock et al., 2002, Baldock et al., 
2005 and Baldock et al., 2006) 
 
3.6. Bone homeostasis following coincident loss of dynorphin and neuropeptide Y signaling 
The involvement of NPY-mediated processes in the skeletal phenotype of Dyn−/− mice was 
further explored by comparison of Dyn−/− with NPY−/− mice and Dyn−/−NPY−/− double 
delete mice. In the distal femoral metaphysis cancellous bone volume was similarly elevated 
in Dyn−/− and NPY−/− mice (Fig. 5A). Importantly, Dyn−/−NPY−/− mice displayed 
equivalently increased cancellous bone volume, with no difference between the three mutant 
genotypes (Fig. 5B). Moreover, trabecular number was similarly increased in the mutant mice, 
consistent with equivalent increases in mineral apposition rate (Fig. 5E). The increase in 
mineralizing surface was not significant in NPY−/− mice, as a result bone formation rate was 
only significantly elevated in Dyn−/− and Dyn−/−NPY−/− models (Fig. 5F and G). Bone 
resorption indices were also similarly altered, with greater osteoclast number and surface in 
the three mutant groups compared to wild type mice (Fig. 5H and I). In contrast, in lumbar 
vertebra, NPY−/− mice were the only group to show a significant skeletal change. Critically, 
the similarity in bone homeostasis between dynorphin and NPY deficiency provide further 
evidence for a single pathway to bone. 
 
4. Discussion 
 
Discovery of the scope and strength of neural influences upon skeletal tissue has been an 
important advance in bone biology in recent years (Driessler and Baldock, 2010). Further 
expanding these unique neuro/skeletal relationships, here we identify a novel interaction 
between the opioid system and bone demonstrating an inhibitory action of dynorphins on 
skeletal tissue, acting through kappa opioid receptors. In particular, loss of dynorphins, one of 
the three endorphin ligand families, induces a skeleton-wide increase in bone mass thereby 
revealing for the first time a connection between opioid signaling and bone mass regulation. 
Moreover, this increase in bone mass in dynorphin knockout animals is most likely due to a 
lack of kappa-mediated stimulation of hypothalamic neuropeptide Y expression. In this 
manner, upregulation of dynorphin and kappa receptor expression, known to occur in 
response to chronic opiate exposure (Wang et al., 1999), may increase central NPY 
expression and – given the known role of hypothalamic NPY expression to inhibit bone 
(Baldock et al., 2009, Baldock et al., 2002, Baldock et al., 2006 and Allison et al., 2006) – 
thereby suppress bone formation and reduce bone mass and strength. Importantly, inhibition 
of this pathway may enable attenuation of the skeletal side-effects of chronic opiate exposure, 
without modulation of the analgesic effects, which occur predominantly through the mu-opioid 
receptor. 
 Dynorphin signaling has been implicated in numerous processes including stress and 
depression, as well as epilepsy and energy homeostasis (Sainsbury et al., 
2007 and Schwarzer, 2009). The current study is the first to identify dynorphin actions in the 
regulation of bone mass and provides a potential link to known opioid side-effects on bone. 
Complete inhibition of dynorphin production was associated with an increase in bone mass, in 
both male and female mice, with a significant increase in calculated bone strength. This 
change was coincident with increased activity of both bone-forming osteoblastic and bone-
resorbing osteoclastic bone cell lineages. Both bone formation and bone resorption were 
increased, with osteoclasts being more common on bone surfaces in Dyn−/− mice. Critically, 
bone formation was increased to a greater degree than bone resorption, with increases in the 
rate at which the bone mineral apposition process occurred, and resulting in a net gain in 
bone mass. 
 Opioid signaling is complex, with numerous ligands acting across several opioid 
receptors, and abundant expression in central and peripheral nervous tissue. However, 
expression of dynorphin and its cognate receptor, the kappa opioid receptor, were not 
detected in primary osteoblastic cultures or whole bone extracts. This result strongly 
suggested a non-local action of dynorphin on bone. Several additional lines of evidence were 
consistent with this hypothesis. Firstly, all opioid receptors and dynorphin were expressed in 
brain extracts, and dynorphin agonist treatment induced robust signaling in neuronal cells;  
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however this was not the case in primary osteoblastic cells. Moreover, primary osteoblastic 
cultures from Dyn−/− mice did not differ from those from wild type with respect to proliferation 
potential, or the ability of differentiated cells to produce alkaline phosphatase in early culture 
or to produce mineralized nodules in late stage cultures. Thus, the dynorphin effect on the 
skeleton does not appear to result from a direct action on the cells of bone or to involve a 
constitutive change in osteoblast activity.	   	  
 In the absence of direct dynorphin signaling, a central axis to bone seems likely. 
Consistent with this, a generalised exposure of central tissues to a KOR agonist induced 
neural activity in the Arc, a region of the hypothalamus that is known to regulate bone mass 
(Baldock et al., 2002 and Elefteriou et al., 2003). Moreover, intra-nuclear injection of kappa 
agonist specifically into the Arc increased the expression of NPY in this hypothalamic 
nucleus. However, this response was absent for mu or delta agonism, indicating a 
dynorphin/kappa specific activation of NPY in the Arc. Importantly, NPY-ergic neurons in the 
hypothalamus have been demonstrated to directly alter bone mass, with an Arc-specific 
expressed in brain extracts, and dynorphin agonist treatment in-
duced robust signaling i neuronal cells; however this was not
the case in pri ary osteoblastic cells. Moreover, primary osteo-
blastic cultures from Dyn!/! mice did not differ from those from
wild type with respect to proliferation potential, or the ability of
differentiated cells to produce alkaline phosphatase in early cul-
ture or to pro uce mineralized nodules in late stage cultures. Thus,
the dynorphin effect on the skeleton does not appear to result from
a direct action on the cells of bone or to involve a constitutive
change in osteoblast activity.
In the absence of direct dynorphin signaling, a ce tral axis to
bone seems likely. Consistent with this, a generalised exposure of
central tissues to a KOR agonist induced neural activity in the
Arc, a region of the hypothalamus that is known to regulate bone
mass (Baldock et al., 2002; Elefteri u et al., 2003). Moreover, in-
tra-nuclear injection of kappa agonist specifically into the Arc
Fig. 5. Similar skeletal effects of dynorphin and neuropeptide Y deletion. (A) Photomicrographs showing that loss of Dyn or NPY increased bone mass in male mice, but dual
mutants do not display greater bone mass then single mutants. (B) Cancellous bone volume and trabecular number (C) were similarly elevated in the three mutant genotypes,
with an increase in trabecular thickness (D) only in NPY!/! and Dyn!/!NPY!/! double mutants. Mineral apposition rate (E) was equally elevated in the three knockout
models, but mineralizing surface (F) and bone formation rate (G) were only significantly elevated in Dyn!/! and DYN!/!NPY!/! mice. Bone resorption indices osteoclast
surface (H) and osteoclast number (I) were also elevated in all mutant genotypes. (J–M) In lumbar vertebrae, as evident in the micro-computed tomography images (J), loss of
NPY but not Dyn increased cancellous bone volume (K) and trabecular number (L) with no change in trabecular thickness (M). Data are means ± 7–10 mice per group.
⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.0001 versus WT, #p < 0.05, ##p < 0.01 for the comparison indicated by horizontal bars.
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increase in NPY expression producing a powerful inhibition of osteoblast activity and 
reduction in bone mass (Baldock et al., 2005 and Baldock et al., 2009). Furthermore, a 
reduction in NPY signaling, as evident in Dyn−/− mice (Baldock et al., 2005, Baldock et al., 
2009, Baldock et al., 2002 and Baldock et al., 2006), is associated with greater bone mass 
and osteoblast activity and calculated bone strength. These data suggest that the increase in 
bone mass in Dyn−/− mice is likely to be a consequence of the reduction in central NPY 
expression, and may thus represent an indirect pathway for dynorphin control of bone mass, 
similar to that reported for dynorphin control of anxiety via NPY-ergic signaling (Wittmann et 
al., 2009). Moreover, this data also implicates increased NPY expression, likely induced by 
greater kappa opioid receptor signaling may represent a possible factor inhibiting bone 
strength under conditions of chronic opiate use. The role for altered hypothalamic NPY 
expression in the regulation of bone mass by opioid signaling is further supported by the 
similarity of skeletal effects in NPY−/−Dyn−/− mice compared to single NPY−/− and Dyn−/− 
knockout mice, suggesting that dynorphin/kappa signaling may act upstream of NPY. This 
similarity was not evident in the vertebrae, suggesting differential homeostasis between axial 
and appendicular skeletons, as demonstrated in other hypothalamic models (Hamrick et al., 
2004). 
 Opioid usage is associated with marked skeletal side effects, with fracture rates 
significantly elevated following treatment (Ensrud et al., 2003). The mechanism involved in 
this reduced bone strength is poorly defined, but processes within the hypothalamus have 
been implicated (Daniell, 2002). Clinically relevant opioid analgesics exert their analgesic 
actions predominantly through MOR (Matthes et al., 1996). However, opiate exposure 
increases both dynorphin expression and that of its cognate receptor, KOR. Thus, in addition 
to MOR signaling, KOR pathways are also stimulated by these drugs, and have been shown 
to mediate, depressive and dysphoric states in these individuals (Pfeiffer et al., 
1986 and Carlezon et al., 1998) and in Dyn−/− mice (Wittmann et al., 2009). As outlined 
herein, such an opiate-mediated increase in dynorphin signaling would also act to stimulate 
NPY expression within the hypothalamus and with it suppression of bone formation. Such 
alterations in hypothalamic neuropeptide activity have been noted previously, with morphine 
treatment reducing pro-opiomelanocortin (POMC) expression in the hypothalamus of rats 
(Zhou et al., 1999). Thus, in addition to well recognized endocrine actions (Fortin et al., 2008) 
opiate exposure may, through stimulation of dynorphin/KOR indirectly suppress osteoblast 
activity through activation of central neuropeptide signaling and subsequent efferent neural 
pathways, as proposed in Fig. 6. 
 While the current study defines NPY as an indirect pathway altering bone mass in 
situations of altered opioid signaling, endocrine pathways have also been suggested. The 
hypogonadism implicit in a subset of cases of opioid-induced osteoporosis has been 
associated with reduced gonoadotrophin release (Daniell, 2002). Dyn−/− mice however, do 
not show altered serum testosterone levels (Sainsbury et al., 2007) suggesting that the Dyn-
mediated effects on bone are mediated independently. Moreover, a number of aspects of the 
Dyn−/− phenotype reinforce the lack of hypogonadism; with reduced rather than increased 
adiposity, no change in longitudinal bone growth, and normal breeding and litter gender 
balance. The reduced adiposity would reduce leptin concentrations, a known bone regulatory 
agent. However, several features of Dyn−/− mice are inconsistent with leptin actions. In the 
brain leptin deficiency results in a marked increase in NPY expression (Sainsbury et al., 
2002), rather than the decrease evident in Dyn−/−; while in bone, ob/ob mice display greater 
cancellous but reduced cortical bone mass and long bone length ( Baldock et al., 
2006 and Hamrick et al., 2004) rather than the consistent increase of Dyn−/−. In the absence 
of an endocrine pathway, this study has therefore furthered the understanding of the 
mechanisms by which hypothalamic processes are involved in the skeletal response to opioid 
signaling and has highlighted the importance and complexity of efferent hypothalamic 
pathways in the peripheral responses to opioid signaling. 
 Taken together, this study identifies the endogenous opioid system as required for 
normal bone homeostasis. The dynorphin/kappa system, possibly acting via NPY, may 
represent a pathway by which higher processes including stress, reward/addiction and 
depression influence skeletal metabolism. Moreover, this may represent one axis whereby 
chronic opioid exposure may inhibit bone formation and strength. Modulation of these 
pathways could provide a novel avenue for attenuation of the adverse skeletal effects of 
exogenous opioid treatment, without compromising their analgesic actions. 
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